Wednesday, July 29, 2026

The Plain Record

Neutral daily news — clear headlines, complete facts.

Business

Johnson & Johnson reaches $5.5 billion settlement in talc cancer lawsuits

Johnson & Johnson reached an estimated $5.5 billion settlement to resolve roughly 76,000 lawsuits alleging its talc products caused ovarian cancer.

Sourced from Reuters
Published July 27, 2026 at 6:47 PM EDT
Johnson & Johnson reaches $5.5 billion settlement in talc cancer lawsuits

The Facts

Who
Johnson & Johnson and approximately 76,000 plaintiffs
What
$5.5 billion settlement agreement for talc lawsuits
When
July 27, 2026
Where
New York and New Jersey
Why
To resolve a decade of litigation regarding claims that talc products caused ovarian cancer.

Timeline of what happened

Key dates and decisions, in the order they occurred.

  1. 2020

    J&J stops selling talc-based baby powder in the U.S.

  2. February 4, 2022

    J&J pursues 'Texas two-step' bankruptcy strategy

  3. March 2, 2025

    Litigation resumes after bankruptcy dismissals

  4. July 27, 2026

    J&J announces $5.5 billion settlement agreement

  5. January 1, 2027

    J&J expects to pay first $3 billion of settlement

Johnson & Johnson (J&J) announced on July 27, 2026, that it has reached an estimated $5.5 billion settlement to resolve tens of thousands of lawsuits alleging that its talc-based baby powder caused ovarian cancer. The agreement aims to settle approximately 76,000 existing claims, representing nearly all current litigation involving the product in federal and state courts.

The settlement follows ten years of legal conflict and follows J&J's three unsuccessful attempts to resolve the claims through a bankruptcy strategy known as a "Texas two-step." During the litigation, the company successfully defended itself in several individual trials, while also facing significant jury verdicts in others. J&J discontinued the sale of talc-based baby powder in the U.S. in 2020, replacing it with a cornstarch-based version.

Erik Haas, J&J’s vice president of litigation, stated that the company chose to settle to achieve closure despite maintaining that the claims are without merit. Chris Seeger, a lead attorney for the plaintiffs, described the deal as a fair resolution that provides higher payments to current claimants over a shorter 18-month period compared to previous settlement proposals.

For the claimants, this agreement changes the timeline for receiving compensation. Unlike the company’s previous bankruptcy proposals, which would have distributed payments over a decade, this deal targets a full payout within 18 months of finalization. For J&J, the settlement represents a significant financial commitment aimed at removing the long-term uncertainty of litigation from its balance sheet, although the deal only covers existing claims and does not prevent future lawsuits from being filed.

The deal establishes a precedent for resolving mass tort litigation through direct negotiation rather than bankruptcy courts. However, the agreement is contingent on a high threshold of approval; at least 95% of the ovarian cancer claimants in both state and federal courts must vote to accept the terms before the settlement becomes final. If that threshold is met, the first large-scale payments are scheduled to begin in 2027.

This story was rewritten from reporting at Reuters. Read the original for full detail.

Summaries are written by The Plain Record to state the facts of a story plainly and without political slant. See our editorial standards, or report a correction.

← Back to the front page